Free Trial
NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

BioXcel Therapeutics logo
$4.05 -0.05 (-1.22%)
Closing price 04:00 PM Eastern
Extended Trading
$3.89 -0.16 (-4.05%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioXcel Therapeutics Stock (NASDAQ:BTAI)

Key Stats

Today's Range
$3.80
$4.09
50-Day Range
$1.31
$6.80
52-Week Range
$1.17
$13.36
Volume
2.70 million shs
Average Volume
28.20 million shs
Market Capitalization
$64.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.75
Consensus Rating
Moderate Buy

Company Overview

BioXcel Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

BTAI MarketRank™: 

BioXcel Therapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 114th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioXcel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    BioXcel Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about BioXcel Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for BioXcel Therapeutics are expected to grow in the coming year, from ($24.39) to ($16.32) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioXcel Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioXcel Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about BioXcel Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.84% of the float of BioXcel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BioXcel Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioXcel Therapeutics has recently decreased by 24.62%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioXcel Therapeutics does not currently pay a dividend.

  • Dividend Growth

    BioXcel Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.84% of the float of BioXcel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BioXcel Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioXcel Therapeutics has recently decreased by 24.62%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BioXcel Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for BioXcel Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    77 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 3,750% compared to the previous 30 days.
  • MarketBeat Follows

    18 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.20% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 30.68% of the stock of BioXcel Therapeutics is held by institutions.

  • Read more about BioXcel Therapeutics' insider trading history.
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BTAI Stock News Headlines

BioXcel Therapeutics (NASDAQ:BTAI) Given "Buy" Rating at HC Wainwright
BioXcel Therapeutics (NASDAQ:BTAI) Cut to Hold at Zacks Research
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
See More Headlines

BTAI Stock Analysis - Frequently Asked Questions

BioXcel Therapeutics' stock was trading at $5.9824 at the beginning of 2025. Since then, BTAI shares have decreased by 32.3% and is now trading at $4.05.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its earnings results on Tuesday, August, 12th. The company reported ($2.45) earnings per share for the quarter, missing analysts' consensus estimates of ($2.30) by $0.15. The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.21 million.

BioXcel Therapeutics shares reverse split on Monday, February 10th 2025.The 1-16 reverse split was announced on Thursday, February 6th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

BioXcel Therapeutics (BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Top institutional investors of BioXcel Therapeutics include Oaktree Capital Management LP (3.98%), Murchinson Ltd. (1.33%), Oaktree Fund Advisors LLC (0.71%) and Geode Capital Management LLC (0.47%). Insiders that own company stock include Vimal Mehta, Richard I Steinhart, Vincent O'neill, Matthew T Wiley, Frank Yocca and Krishnan Nandabalan.
View institutional ownership trends
.

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioXcel Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE) and Saia (SAIA).

Company Calendar

Last Earnings
8/12/2025
Today
8/29/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BTAI
CIK
1720893
Fax
N/A
Employees
90
Year Founded
2017

Price Target and Rating

High Price Target
$80.00
Low Price Target
$4.00
Potential Upside/Downside
+881.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($12.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$59.60 million
Net Margins
-5,869.82%
Pretax Margin
-5,869.82%
Return on Equity
N/A
Return on Assets
-134.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.76
Quick Ratio
0.74

Sales & Book Value

Annual Sales
$868 thousand
Price / Sales
74.70
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($6.73) per share
Price / Book
-0.60

Miscellaneous

Outstanding Shares
16,009,000
Free Float
12,615,000
Market Cap
$64.84 million
Optionable
Optionable
Beta
0.05

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:BTAI) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners